Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis.
Intestinal pseudoobstruction and pneumatosis cystoides intestinalis are uncommon complications of progressive systemic sclerosis. We report a 26-year-old woman with this disorder who responded poorly to conventional treatment. Subcutaneous administration of octreotide, a long-acting somatostatin analogue, at a dose of 50 micrograms/day for 3 weeks, relieved symptoms such as nausea and bloating. There was also a marked decrease of intestinal gas accumulation, as documented on X-ray films.
Kobayashi
T
T
Department of Internal Medicine. Asama General Hospital, Saku, Japan.
Kobayashi
M
M
Naka
M
M
Nakajima
K
K
Momose
A
A
Toi
M
M
D000328:Adult; D003131:Combined Modality Therapy; D015237:Dinoprost / Q000627:therapeutic use; D004294:Domperidone / Q000627:therapeutic use; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007418:Intestinal Pseudo-Obstruction / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D015282:Octreotide / Q000494:pharmacology / Q000627:therapeutic use*; D011006:Pneumatosis Cystoides Intestinalis / Q000188:drug therapy* / Q000209:etiology; D012595:Scleroderma, Systemic / Q000150:complications* / Q000188:drug therapy
D004294:Domperidone; D015237:Dinoprost; D015282:Octreotide